SOURCE: Eisai Inc.

September 13, 2005 08:00 ET

Eisai Inc. and U.S. Pharmacist Honor Pharmacists for Outstanding Service to Patients With Alzheimer's Disease

Fourth Annual hhc (human health care) Pharmacy Recognition Award Acknowledges Excellence in Alzheimer's Disease Education and Patient Care

TEANECK and BLOOMFIELD, NJ -- (MARKET WIRE) -- September 13, 2005 -- Eisai Inc. and U.S. Pharmacist announce today the recipients of the Fourth Annual hhc (human health care) Pharmacy Recognition Award. The award acknowledges pharmacists who provide professional services to people affected by Alzheimer's disease by implementing programs to address issues such as early recognition, appropriate treatment and family caregiving.

Named for the company's human health care mission, the hhc Pharmacy Recognition Award emphasizes Eisai's commitment to satisfy unmet medical needs and to increase benefits to patients and their families. The award recognizes pharmacists who have helped to enhance the quality of care for Alzheimer's patients either through screening and counseling or by educating caregivers and healthcare providers. As the discoverer and developer of Aricept® (donepezil hydrochloride tablets), the number-one prescribed medication worldwide for mild-to-moderate Alzheimer's disease, Eisai is committed to supporting people affected by this chronic disease.

"We view pharmacists as valued partners in the delivery of quality healthcare, providing appropriate medication, counseling and support for their customers," said Lonnel Coats, president & COO of Eisai Inc., a Teaneck, NJ-based pharmaceutical company. "Sponsoring this award with U.S. Pharmacist allows us to recognize those individuals who make an extraordinary effort in increasing benefits to patients and their families."

"The hhc Pharmacy Recognition Award highlights the important role pharmacists play in contributing to the health and well-being of their community," said Harold E. Cohen, R.Ph., editor-in-chief of U.S. Pharmacist, a monthly journal that provides pharmacists with information relevant to contemporary pharmacy practice. "We applaud this year's recipients for their outstanding dedication to improving the lives of patients with Alzheimer's disease."

The awards are intended for four licensed pharmacists practicing in a variety of settings who have been involved in education or disease-state management of patients with Alzheimer's disease within the past 12 months.

The four recipients are:

--  Heather Allison Greene, PharmD, who is recognized for her work in the
    Community Pharmacy category.  Dr. Greene developed and implemented a
    program to obtain reimbursement for pharmacy clinical services at Plaza
    Professional Pharmacy in Richmond, VA, that provides services -- including
    a multi-factorial fall prevention program, self-medication evaluations,
    memory screening, medication regimen reviews, and a cognitive health
    awareness program -- to a large geriatric living facility.  Dr. Greene also
    has participated in the Virginia GranDriver Campaign, which educates
    seniors about how medications may affect their ability to drive.
    Additionally, in her position as clinical instructor at Virginia
    Commonwealth University School of Pharmacy, she developed and taught a
    course in geriatric pharmacy and has lectured at national and local
    pharmacy meetings.
    
--  David P. Elliot, PharmD, FASCP, FCCP, who is recognized for his work
    in the Long-Term Care Pharmacy category.  Dr. Elliot regularly assists
    patients with dementia at the Geriatric Assessment Clinic at West Virginia
    University and further serves patients with Alzheimer's disease through his
    work with the Mountain State Geriatric Center Interdisciplinary Curriculum
    committee.  In his role as a faculty member at the university, Dr. Elliot
    oversees geriatric rotations in long-term and ambulatory care.  His
    research interests include investigating methods to monitor the effects of
    treatments for Alzheimer's disease and depression in older adults, and he
    has authored numerous articles on dementia and Alzheimer's disease.
    
--  Kimberly A. Capuzzo, PharmD, CGP, who is recognized for her work in
    the Institutional Pharmacy category.  Dr. Capuzzo established the clinical
    pharmacy component of the Geriatric Consult Service at Virginia
    Commonwealth University Medical Center where she serves as a clinical
    pharmacist.  Her duties include medication management, drug regimen review,
    implementation and monitoring of drug therapy, as well as providing drug
    information to healthcare professionals and patients, the vast majority of
    whom have dementia.  Dr. Capuzzo also participates in the Housecall
    Program, assisting patients with Alzheimer's disease in their homes.
    
--  Myra T. Belgeri, PharmD, CGP, FASC, who is recognized with an
    Institutional Pharmacy award.  Dr. Belgeri serves as an ambulatory care
    clinical pharmacist with a specialty in geriatrics at the St. Louis VA
    Medical Center.  Approximately 30 to 40 percent of the patients she sees
    have been identified as having some form of dementia. To address this, Dr.
    Belgeri has implemented programs that utilize multiple cognitive screening
    tools to identify those patients with Alzheimer's disease and other
    dementia-related conditions.  She also performs medication reconciliation
    and medication education.
    
In addition to receiving a specially designed keepsake plaque and an honorarium, each of the winners will be profiled in a two-page article in U.S. Pharmacist (October through December 2005).

About Eisai Inc.

Eisai Inc. is a US pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products in more than 30 countries. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2 billion in fiscal year 2004 (year ended March 31, 2005).

Eisai Inc. employs approximately 1,200 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. Between 1998 and 2004, Eisai Inc. moved up rapidly in the rankings (based on revenues) of US pharmaceutical companies from No. 44 to No. 19.

About U.S. Pharmacist

U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management.

Information About ARICEPT Treatment in Alzheimer's disease

While there is no cure for Alzheimer's disease, medical treatments are available to help manage symptoms of the disease. Once-a-day prescription ARICEPT® is indicated for mild to moderate Alzheimer's disease.

In a progressively degenerative disease such as Alzheimer's, improvement, stabilization or a less-than-expected decline over time is considered a positive response to treatment. These types of responses have been observed in patients treated with ARICEPT in clinical trials for Alzheimer's disease. Individual responses to treatment vary, and some patients may not respond.

ARICEPT is well tolerated but may not be for everyone. Some people may have nausea, diarrhea, not sleep well or vomit. Some people may have muscle cramps, feel very tired or may not want to eat. In studies, these side effects were usually mild and went away over time. People at risk for stomach ulcers or who take certain other medicines should tell their doctors, because serious stomach problems, such as bleeding, may get worse. Some people who take ARICEPT may experience fainting.

ARICEPT is the number one prescribed Alzheimer's disease therapy worldwide, with more than 1 billion patient days of ARICEPT therapy. More than 1.7 million people in the United States alone have begun ARICEPT therapy.

ARICEPT® (donepezil HCl tablets) was discovered and developed and is manufactured and distributed by Eisai.

For more information about managing Alzheimer's disease and about ARICEPT, see accompanying full prescribing information or call (888) 999-9616 or visit www.aricept.com.

Contact Information

  • Contacts:
    Cathy Pollini
    Eisai Inc.
    201-287-2052

    Harold Cohen
    U.S. Pharmacist
    973-954-9223

    Anna Blank
    Hill & Knowlton
    212-885-0522